Prestige BioPharma registers Ph I study of PBP1502 (proposed adalimumab biosimilar)

Dec 7, 2021

Prestige BioPharma announced that its Ph I study of PBP1502 (proposed adalimumab biosimilar) has been registered with the US National Institute of Health.  Prestige disclosed that it plans to file marketing authorisation applications with the EMA and FDA in 2023.

Print Page Mail Article